Zomig-zmt is a drug owned by Astrazeneca Pharmaceuticals Lp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 14, 2013. Details of Zomig-zmt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5466699 (Pediatric) | Indolyl compounds for treating migraine |
May, 2013
(11 years ago) |
Expired
|
| US5466699 | Indolyl compounds for treating migraine |
Nov, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Zomig-zmt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zomig-zmt's family patents as well as insights into ongoing legal events on those patents.
Zomig-zmt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zomig-zmt's generic launch date based on the expiry of its last outstanding patent is estimated to be May 14, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zomig-zmt Generic API suppliers:
Zolmitriptan is the generic name for the brand Zomig-zmt. 18 different companies have already filed for the generic of Zomig-zmt, with Macleods Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zomig-zmt's generic
Alternative Brands for Zomig-zmt
There are several other brand drugs using the same active ingredient (Zolmitriptan) as Zomig-zmt. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Zolmitriptan, Zomig-zmt's active ingredient. Check the complete list of approved generic manufacturers for Zomig-zmt
About Zomig-zmt
Zomig-Zmt is a drug owned by Astrazeneca Pharmaceuticals Lp. Zomig-Zmt uses Zolmitriptan as an active ingredient. Zomig-Zmt was launched by Astrazeneca in 2001.
Approval Date:
Zomig-zmt was approved by FDA for market use on 13 February, 2001.
Active Ingredient:
Zomig-zmt uses Zolmitriptan as the active ingredient. Check out other Drugs and Companies using Zolmitriptan ingredient
Dosage:
Zomig-zmt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2.5MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 5MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |